Objectives: Interferon-β 1a (IFN-β 1a) is a common strategy therapy for multiple sclerosis (MS) with unknown mechanisms. S100A12 (S100 calcium-binding protein A12) is a damage-associated molecular pattern molecule which binds to its receptor, RAGE (receptor for advanced glycation end products), and activates nuclear factor-κB (NF-κB). NF-κB is transcribed from proinflammatory molecules, which may participate in the pathogenesis of MS. Therefore, the aims of this study were to compare mRNA levels of S100A12, RAGE, and NF-κB in newly diagnosed MS patients with healthy controls and determine whether IFN-β 1a therapy affects the expression of the molecules. Methods: S100A12, RAGE, and NF-κB mRNA levels in 30 new cases of untreated MS patients and 35 healthy controls were evaluated using the real-time PCR technique. The mRNA levels were also evaluated in the MS patients after 6 months of IFN-β 1a therapy. Results: S100A12, RAGE, and NF-κB mRNA levels were significantly decreased in the new cases of untreated MS patients in comparison to healthy controls. IFN-β 1a therapy results in upregulation of RAGE in MS patients, but not S100A12 and NF-κB. Conclusions: It appears that S100A12 participates in the pathogenesis of MS, and it seems that IFN-β 1a modulates immune responses in an S100A12-independent manner. Based on the reported anti-inflammatory effects of RAGE, it seems that RAGE may be considered as a mechanism by IFN-β 1a to modulate immune responses. NF-κB is produced permanently in the human cells and is inactive in the cytoplasm; therefore, the effects of IFN-β 1a may be related to its functions rather than expressions.

Keywords:
IFN-β 1a, Multiple sclerosis, S100A12, RAGE, Nuclear factor-κB
1.
Etemadifar M, Fatehi F, Sahraian M, Borhanihaghighi A, Ardestani P, Kaji-Esfahani M, Maghzi A: Multiple sclerosis and neurofibromatosis type 1: report of seven patients from Iran. Mult Scler 2009;15:1126-1130.
2.
Noroozi S, Meimand HA, Arababadi MK, Nakhaee N, Asadikaram G: The effects of IFN-β 1a on the expression of inflammasomes and apoptosis-associated speck-like proteins in multiple sclerosis patients. Mol Neurobiol 2016, Epub ahead of print.
3.
Revel M: Interferon-beta in the treatment of relapsing-remitting multiple sclerosis. Pharmacol Ther 2003;100:49-62.
4.
Qizilbash N, Mendez I, Sanchez-de la Rosa R: Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis. Clin Ther 2012;34:159-176.e5.
5.
Ebrahimi HA, Sedighi B: Prevalence of multiple sclerosis and environmental factors in Kerman Province, Iran. Neurol Asia 2013;18:385-389.
6.
Peiravian F, Rajaian H, Samiei A, Gholijani N, Gharesi-Fard B, Mokaram P, Rahimi-Jaberi A, Kamali Sarvestani E: Altered serum cytokine profiles in relapse phase of relapsing-remitting multiple sclerosis. Iran J Immunol 2016;13:186-196.
7.
Zare-Bidaki M, Hakimi H, Abdollahi SH, Zainodini N, Arababadi MK, Kennedy D: TLR4 in toxoplasmosis; friends or foe? Microb Pathog 2014;69-70:28-32.
8.
Sepehri Z, Kiani Z, Alavian SM, Arababadi MK, Kennedy D: The link between TLR7 signaling and hepatitis B virus infection. Life Sci 2016;158:63-69.
9.
Kang JH, Hwang SM, Chung IY: S100A8, S100A9 and S100A12 activate airway epithelial cells to produce MUC5AC via extracellular signal-regulated kinase and nuclear factor-κB pathways. Immunology 2015;144:79-90.
10.
Lindholm B: Serum S100A12: a risk marker or risk factor of vascular calcification in chronic kidney disease. Am J Nephrol 2015;42:1-3.
11.
Panitch HS: Interferons in multiple sclerosis. Drugs 1992;44:946-962.
12.
Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
13.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
14.
Ebrahim M, Mirzaei V, Bidaki R, Shabani Z, Daneshvar H, Karimi-Googheri M, Khaleghinia M, Afrooz MR, Yousefpoor Y, Kazemi Arababadi M: Are RIG-1 and MDA5 expressions associated with chronic HBV infection? Viral Immunol 2015;28:504-508.
15.
Hou F, Wang LK, Wang H, Gu JC, Li ML, Zhang JK, Ling X, Gao XF, Luo C: Elevated gene expression of S100A12 is correlated with the predominant clinical inflammatory factors in patients with bacterial pneumonia. Mol Med Rep 2015;11:4345-4352.
16.
Glasnović A, Cvija H, Stojić M, Tudorić-Đeno I, Ivčević S, Romić D, Tičinović N, Vuletić V, Lazibat I, Grčević D: Decreased level of sRAGE in the cerebrospinal fluid of multiple sclerosis patients at clinical onset. Neuroimmunomodulation 2014;21:226-233.
17.
Oesterle A, Bowman MA: S100A12 and the S100/calgranulins: emerging biomarkers for atherosclerosis and possibly therapeutic targets. Arterioscler Thromb Vasc Biol 2015;35:2496-2507.
18.
Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781-25790.
19.
Nguyen LT, Ramanathan M, Weinstock-Guttman B, Baier M, Brownscheidle C, Jacobs LD: Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci 2003;209:93-99.
20.
Karimi-Googheri M, Arababadi MK: TLR3 plays significant roles against hepatitis B virus. Mol Biol Rep 2014;41:3279-3286.
21.
Bagheri V, Askari A, Arababadi MK, Kennedy D: Can Toll-like receptor (TLR) 2 be considered as a new target for immunotherapy against hepatitis B infection? Hum Immunol 2014;75:549-554.
22.
Sun H, Kamanova J, Lara-Tejero M, Galan JE: A family of salmonella type III secretion effector proteins selectively targets the NF-κB signaling pathway to preserve host homeostasis. PLoS Pathog 2016;12:e1005484.
23.
Haarmann A, Nehen M, Deiss A, Buttmann M: Fumaric acid esters do not reduce inflammatory NF-κB/p65 nuclear translocation, ICAM-1 expression and T-cell adhesiveness of human brain microvascular endothelial cells. Int J Mol Sci 2015;16:19086-19095.
24.
Zilkha-Falb R, Gurevich M, Hayardeny L, Achiron A: The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: lessons from gene expression signatures. J Neuroimmunol 2015;283:11-16.
25.
Yi H, Bai Y, Zhu X, Lin L, Zhao L, Wu X, Buch S, Wang L, Chao J, Yao H: IL-17A induces MIP-1α expression in primary astrocytes via Src/MAPK/PI3K/NF-κB pathways: implications for multiple sclerosis. J Neuroimmune Pharmacol 2014;9:629-641.
26.
Eggert M, Goertsches R, Seeck U, Dilk S, Neeck G, Zettl UK: Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy. J Neurol Sci 2008;264:145-150.
27.
Housley WJ, Fernandez SD, Vera K, Murikinati SR, Grutzendler J, Cuerdon N, Glick L, De Jager PL, Mitrovic M, Cotsapas C, Hafler DA: Genetic variants associated with autoimmunity drive NFκB signaling and responses to inflammatory stimuli. Sci Transl Med 2015;7:291ra293.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.